Total neoadjuvant therapy with concurrent tislelizumab for low rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-arm multi-center study gives all participants 4–6 cycles of total neoadjuvant therapy combined with the PD-1 antibody tislelizumab, followed by a clinical response assessment. Patients who achieve a complete response (clinical CR or pathologic CR after local resection for near-CR) continue tislelizumab plus CAPOX for four more cycles and then receive tislelizumab alone for nine cycles before entering a Watch-and-Wait program. Patients who do not reach CR proceed to standard total mesorectal excision (TME). Key eligibility includes adults 18–75 with histologically confirmed low rectal adenocarcinoma within 3 cm of the dentate line, resectable cT1–3 N0–1 M0 disease, pMMR or MSS/MSI-L status, ECOG 0–1, and no prior anti-tumor treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able to provide written informed consent, understand and comply with the requirements and evaluation schedule
2. ≥18, ≤75 years old
3. Histologically confirmed rectal adenocarcinoma
4. immunohistochemistry confirmed pMMR (positive for MLH1, MSH2, MSH6 and PMS2), or PCR /NGS confirmed MSI-L or MSS
5. The tumor is within 3 cm of the dentate line. through colonoscopy, digital anal examination or MRI
6. clinical stage cT1-3 N 0-1M0 (the 8th UICC/AJCC; T and N is evaluated by MRI)
7. Resectable primary tumor assessed by the Investigator
8. Have not received any anti-tumor treatment for rectal cancer
9. ECOG PS ≤ 1
10. Adequate organ function
11. Female subjects with the ability to become pregnant must have a serum pregnancy test with a negative result within 72 hours before the first dose, and be willing to use highly effective contraceptive methods during the trial and 120 days after the last dose. Male subjects whose partners are women of childbearing potential should be surgically sterilized or agree to use a highly effective method of contraception during the trial and for 120 days after the last dose.

Exclusion Criteria:

1. Histologically confirmed poorly differentiated/undifferentiated adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma
2. Have received any treatments for rectal cancer, or evidence of distant metastasis
3. Presence of following high risk factors assessed by MRI: MRF +, EMVI+, cN2, Positive lateral lymph nodes, T3d
4. Presence or in high risk of obstruction, perforation or bleeding;
5. Not suitable for long-course radiotherapy
6. Cannot tolerate surgery
7. ≥2 colorectal cancer lesions at the same time
8. Contraindications for MRI examination
9. Other malignant tumors in the past or at the same time
10. Have an active autoimmune disease requiring systemic therapy within the past 2 years
11. HIV infection
12. Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA \> 500 IU/mL) or active HCV carriers with detectable HCV RNA;
13. Hypersensitivity to any ingredient of tislelizumab, capecitabine, and oxaliplatin or to any component of the container
14. Other conditions judged by the researcher that do not meet the enrollment requirements

Where it's running

• Shanghai Zhongshan Hospital, Shanghai
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jianmin Xu, MD
• Email: xujmin@aliyun.com
• Phone: +862164041990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant chemoradiotherapy with or without tislelizumab for ultra-low rectal cancer – RELIEVE-02

  This study tests whether adding tislelizumab to standard chemoradiotherapy and subsequent chemotherapy improves anus preservation in adults with resectable ultra-low rectal cancer.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07132463

• Neoadjuvant radiotherapy with toripalimab, liposomal irinotecan, and capecitabine for pMMR locally advanced low rectal cancer

  This trial will test whether adding toripalimab, liposomal irinotecan, and capecitabine to radiation before surgery helps adults with pMMR locally advanced low rectal cancer.

  Recruiting Phase 2 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong and 1 other locations · NCT07104604

• Effects of Tislelizumab with Chemotherapy in Advanced Rectal Cancer

  This study is testing if adding a new drug called Tislelizumab to chemotherapy can help people with advanced rectal cancer have better outcomes before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Guangxi Medical University · Nanning, Guangxi · NCT06254521

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.